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Research Article
Understanding longitudinal biventricular structural and
functional changes in a pulmonary hypertension Sugen–
hypoxia rat model by cardiac magnetic resonance imaging
Geeshath Jayasekera1,* , Kathryn S. Wilson2,*, Hanna Buist2, Rosemary Woodward1,
Aysel Uckan1, Colin Hughes3, Margaret Nilsen1, A Colin Church2, Martin K. Johnson2,
Lindsay Gallagher4, James Mullin4, Mandy R. MacLean1, William M. Holmes4,
Andrew J. Peacock2,* and David J. Welsh2,*
1ICAMS, University of Glasgow, Glasgow, UK; 2Scottish Pulmonary Vascular Unit, Glasgow Caledonian University, Glasgow, UK; 3CRF, University of Glasgow,
Glasgow, UK; 4GEMRIC, INP, University of Glasgow, Glasgow, UK
Abstract
Cardiac magnetic resonance-derived ventricular variables are predictive of mortality in pulmonary arterial hypertension. Rodent
models which emphasize ventricular function, allowing serial monitoring, are needed to identify pathophysiological features and
novel therapies for pulmonary arterial hypertension. We investigated longitudinal changes in the Sugen–hypoxia model during
disease progression. Sprague Dawley rats (n¼ 32) were divided into two groups. (1) Sugen–hypoxia: a dose of subcutaneous Sugen-
5416 and placed in hypobaric hypoxia for two weeks followed by normoxia for three weeks. (2) Normoxia: maintained at normal
pressure for five weeks. Rats were examined at five or eight weeks with right-heart catheter, cardiac magnetic resonance, and
autopsy. Compared to normoxic controls (23.9 4.1 mmHg), right ventricular systolic pressure was elevated in Sugen–hypoxia
rats at five and eight weeks (40.9 15.5 mmHg, p¼ 0.026; 48.9 9.6 mmHg, p¼ 0.002). Right ventricular end-systolic volume
index was increased in eight weeks Sugen–hypoxia (0.28 0.04 mlcm–2, p¼ 0.003) compared to normoxic controls (0.18
0.03 mlcm–2). There was progressive dilatation of the right ventricular at eight weeks Sugen–hypoxia compared to normoxic
controls (0.75 0.13 mlcm–2 vs 0.56 0.1 mlcm–2 p¼ 0.02). Ventricle mass index by cardiac magnetic resonance at five weeks
(0.34 0.06, p¼ 0.003) and eight weeks Sugen–hypoxia (0.34 0.06, p¼ 0.002) were higher than normoxic controls (0.21 0.04).
Stroke volume, right ventricular ejection fraction, and left ventricular variables were preserved in Sugen–hypoxia. Ventricular
changes during the course of illness in a pulmonary arterial hypertension rodent model can be examined by cardiac magnetic
resonance. These changes including right ventricular hypertrophy and subsequent dilatation are similar to those seen in pulmonary
arterial hypertension patients. Despite the persisting pulmonary hypertension, there are features of adaptive cardiac remodeling
through the study duration.
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Introduction
Pulmonary arterial hypertension (PAH) is a disease of the
pulmonary vasculature; however, it is subsequent right ven-
tricular (RV) failure that is the main cause of morbidity and
mortality in patients. Cardiac magnetic resonance (CMR)
is a non-invasive imaging tool providing high-resolution
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three-dimensional images of the heart. During CMR, ven-
tricular short axis stacks are used to reconstruct a 3D image
of the right and the left ventricle (LV), and ventricular
volumes, mass, and function can be measured.1 Many
CMR measurements have shown to be strongly predictive
of mortality and survival thus offering potential for assess-
ing response to treatment. Stroke volume,2 RV ejection frac-
tion,3 and RV and LV end-diastolic volume (EDV)4 have all
shown to be prognostic markers in PAH patients.
Small animal (rodent) models are increasingly used to
identify pathophysiology as well as therapies for PAH
with the intention of translating findings to humans.
Accurate monitoring of disease in rodents with emphasis
on ventricular function (rather than right heart catheteriza-
tion alone) without killing the animal is needed.
Various rodent models to recapitulate human PAH have
been produced. Sugen-5416 (Sugen), an inhibitor of vascular
endothelial growth factor was shown to cause a mild rise
in pulmonary artery pressure in wild-type rats. Combining
Sugen with another stimulus of pulmonary hypertension
(PH), i.e. chronic hypoxia, Taraseviciene-Stewart et al.
described the Sugen–hypoxia (SuHx) rat model in 2001.5 A
combination of Sugen and chronic hypoxia cause pulmonary
endothelial cell death and severe PH. Subsequently in 2010,
Abe et al. showed that SuHx rats demonstrated evidence of
severe pulmonary arteriopathy including concentric neo-inti-
mal and complex plexiform-like lesions which closely resem-
ble plexiform lesions seen in humans.6 Subsequently, other
groups have attempted to characterize hemodynamics in a
SuHx model beyond right heart catheterization alone. Vitali
et al. evaluated longitudinal changes in a SuHx mouse model
of PH. Echocardiographic and invasive measurements were
performed after three weeks of hypoxia and after 10 weeks
of recovery in normoxia. Ten weeks after hypoxic exposure,
RV systolic pressure (RVSP) had decreased, but remained
elevated compared to normoxic controls. However, RV
hypertrophy had resolved. They observed very few angio-
obliterative lesions at 10 weeks.7 De Raaf et al. used telemetry
to characterize hemodynamics in SuHx rats and associated
these with serial histology.8 Jones et al. demonstrated a good
correlation between M-mode and Doppler Echo vs right
heart catheterization in the monocrotaline rat model.9 In a
study by Urboniene et al. assessing validation of high
resolution echocardiography and CMR vs high fidelity cath-
eterization in experimental PH monocrotaline rat model,
non-invasive measures of RV free wall thickness/mass corre-
lated well with post mortem measurements.10
Our group has a proven track record using CMR imaging
to evaluate RV function in humans with PAH.4,11,12 The
same non-invasive and repeatable measurements would be
of great advantage for the study of rodent models to allow a
detailed understanding of ventricular structural and func-
tional changes that occur, to enhance efficacy in transla-
tional medicine. We investigated whether CMR is feasible
in a SuHx rat model of PH. Subsequently, we investigated
the structural and functional changes associated with the
model during disease progression. Finally, we discussed
the suitability of the SuHx model for translational studies
of the mechanisms of RV dysfunction in PAH.
Methods
Ethics
All experimental procedures were carried out in accordance
with the United Kingdom Animal Procedures Act (1986)
and with the US NIH publication No. 85-23, revised 1996,
and ethical approval was also granted by the University of
Glasgow Ethics Committee. Rodents were housed in a 12-h
light–dark cycle with access to food and water ad libitum.
Study design
Male Sprague Dawley rats (three weeks) (n¼ 32) were
divided into two groups (n¼ 16 in each group). Group 1:
SuHx—a single dose of subcutaneous Sugen-5416 (Sigma,
UK) suspended in vehicle (20mg/kg), before being placed in
a hypobaric chamber (atmospheric pressure 550 mbar) for
two weeks and then placed in normal room pressure (1013
mbar) for three weeks whilst PH developed. Group 2:
Normoxia—maintained at normal room pressure for five
weeks. In each group (n¼ 16), half the animals entered the
CMR arm of the study (n¼ 8) while the other half under-
went right heart catheterization for hemodynamic assess-
ment (n¼ 8). Animals were assessed at five weeks and
eight weeks from the beginning of the study. The study
design is summarized in Fig. 1.
In vivo hemodynamic measurements
Animals were anesthetically induced with 3% (v/v) isoflurane
and then maintained at 2% (v/v) isoflurane supplemented
with a constant flow of 5% (v/v) oxygen. Hemodynamic
measurements were taken using an ultra-miniature
Polyimide Nylon catheter capable of measuring ventricular
pressure continuously (AD Instruments SPR-869NR,
Millar). The catheter was used as per the manufacturer’s
instructions with the PowerLab 35 Series data acquisition
system with LabChart Pro and the pressure volume (PV)
loop analysis module. For right heart pressure analysis, the
catheter was inserted into the jugular vein and guided into the
RV to measure RVSP.
RV hypertrophy and tissue harvest
Following hemodynamic assessment, animals were culled
and hearts flushed with phosphate buffered saline using a
blunt needle to clear peripheral blood cells. Euthanasia con-
sisted of an overdose of anesthetic followed by a schedule 1
kill (cervical dislocation). The heart was isolated, atria
removed, and tissue fixed with 10% (v/v) neutral buffered
formalin for 48 h before paraffin processing for histological
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analysis by immunohistochemistry. Tissue was sectioned by
microtome at width of 5 mm and stained by Gomori’s tri-
chrome staining kit (Atom Scientific, Manchester, UK) as
per manufacturer’s instructions.
Gross anatomy postpartum
After the heart was isolated and atria removed, the RV and
LV weights were obtained to determine RV hypertrophy.
Interventricular septum was considered part of the LV.
Pulmonary vascular remodeling
Vascular thickening was determined by smooth muscle actin
antibody (ab5694, Abcam, Cambridge, UK) staining,
thickening was characterized by an increase in the vessel
wall diameter of more than 50% of the arterial wall or com-
plete occlusion. The number of remodeled vessels over the
total number of vessels present in a lung section was deter-
mined. Sections were analyzed in a blinded manner.
CMR
CMR imaging was performed in a Bruker Biospec 7-T/
30-cm (Bruker Biospin, Ettlingen, Germany) system with a
gradient coil insert (400mT/m). Using a 72-mm transmit
birdcage resonator and four channel phased array rat car-
diac receiver coil. Anesthesia was induced with gas flow at
2–3 l/min, and the isoflurane delivered via a vaporizer
(Vetamac, Rossville, IN) at 3–4%. The exhaust was con-
nected to the Omnicon F/Air device (AM Bickford). After
induction, animals were maintained at 2% (v/v) isoflurane
supplemented with a constant flow of 5% (v/v) oxygen.
An external water jacket was used to maintain a core tem-
perature of 37C. During all procedures, body temperature,
ECG, and respiration were monitored (Echo: Indus
Instruments, Houston, TX; MRI: SA Instruments, Stony
Brook, NY; Cath: Powerlab, AdInstruments, Colorado
Springs, CO). Long and short axis scout images were
acquired so that short axis images could be planned using
a segmented, cardiac-triggered FLASH sequence. The
images were acquired with a slice thickness of 1.5mm,
ensuring the entire biventricular length is covered. The
CMR parameters were as follows. Slice thickness—1.50mm,
field of view—30.00mm 30.00mm, image matrix—
192 192 pixels, image resolution—156 mm 156 mm, Flip
angle—15 degrees, Echo time—2.50ms, Rep. time—
7.02ms, number of frames—25, number of averages—6,
and software version—Paravision 5.1.
CMR analysis
Scans were coded by number and analyzed in batches by G.J
who was blinded to the identity and hemodynamic results at
the time of analysis. A second observer (A.U) analyzed five
scans for inter-rater agreement analysis. Trabeculations and
papillary muscles were considered as part of the blood pool.
The epicardial and endocardial borders were manually out-
lined in end-diastolic and end-systolic frames using QMass
(MEDIS, Netherlands). Stroke volume was determined from
EDV – end-systolic volume (ESV) of the LV. Ejection frac-
tion ((SV/EDV) 100%) was also determined. RV and LV
masses were determined by manual planimetry at diastole.
Ventricular mass index (VMI) was defined as the ratio
between RV to LV mass, with the interventricular septum
considered part of the LV. LV eccentricity index (LVEI)
was defined as the ratio between maximum anterior–posterior
to septal lateral diameters of the LV and was measured at
both systole and diastole. All ventricular volumes and mass
measurements were indexed to body surface area.13
Fig. 1. The study design summarized. Male Sprague Dawley rats (n¼ 32) were divided into two groups (n¼ 16 in each group). Group 1: Sugen–
hypoxia (SuHx)—a single dose of Sugen-5416, before being placed in a hypobaric chamber for two weeks and then placed in normal room
pressure for three weeks whilst PH developed, animals receive control chow throughout. Group 2: normoxic maintained at normal room
pressure for five weeks. In each group, half the animals entered the cardiac MRI arm of the study (n¼ 8) while the other half underwent right
heart catheterization for hemodynamic assessment (n¼ 8). Animals were assessed at five weeks and eight weeks from the beginning of the study
with right heart catheterization, CMR, and gross anatomy at autopsy.
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Statistical analysis
Ventricular volumes and mass are given as mlcm–2 and
mgcm–2, respectively, indexed for body surface area.
Statistical analysis was performed using SPSS (IBM, SPSS
Statistics, USA) and GraphPad Prism (GraphPad, USA).
A significance level of 0.05 was employed for statistical
tests. An analysis of variance test was used to compare
RV and LV mass, volumes, and function between normoxic
animals and different stages of SuHx. If there was statistical
significance, a Tukey test was used for post hoc analysis.
To compare different methods of VMI measurement
(CMR vs autopsy), a spearmen correlation was used.
Inter-rater variability for determination of LV and RV func-
tion were calculated from paired measurements of the LV
ejection fraction (LVEF) and RV ejection fraction (RVEF)
of two readers as interclass correlation coefficient with a
two-way mixed model for absolute agreement. Results are
shown as mean SD unless otherwise stated.
Results
Right heart catheterization and RV hypertrophy
Compared to normoxic rats (23.87 4.1mmHg), RVSP was
significantly elevated in SuHx rats at both five and eight
weeks (40.95 15.5mmHg, p¼ 0.03; 48.89 9.6mmHg,
p¼ 0.002, respectively). There were no significant differences
in RVSP between SuHx rats at five and eight weeks.
Similarly, relative RV mass measured at autopsy by RV/
(LVþ septum) was significantly elevated at five weeks
(0.36 0.1, p¼ 0.021) and eight weeks (0.4 0.04,
p¼ 0.004) SuHx compared to controls (0.25 0.04) (Fig. 2).
Immunohistochemical analysis of a-smooth muscle actin
staining in the smooth muscle layer of small pulmonary
arteries of the lungs demonstrated vascular thickening and
remodeling at both five and eight weeks of SuHx. Although
there was statistical significant difference between the percent-
age of remodeled vessels between normoxia and SuHx
groups (57.4% 7.3 vs 77.6% 10.3, p¼ 0.02; 57.4% 7.3
vs 78.5% 9.4, p¼ 0.02), there was no significant difference
observed between SuHx rats at five and eight weeks (Fig. 2).
CMR
A representative long axis image (a) and a short axis cine
stack (b) to (f) are shown in Fig. 3. The LV and the RV
demonstrated good spatial and temporal resolution allowing
manual planimetry. All of the images in normoxic or SuHx
animals were suitable for analysis. Initial scout images were
acquired to identify the cardiac chambers.
Inter-rater variability
Therewas excellent agreement between the twoobservers (ICC:
Intra class correlation coefficient 0.97, 95%CI: 0.74–1.0) for
LVEF as well as for RVEF (ICC: 0.96, 95%CI: 0.64–1.0).
Right ventricle
RVESV index was significantly increased in SuHx rats at
eight weeks (0.28 0.04, p¼ 0.003) compared to normoxic
rats (0.18 0.03). There were no significant differences
between normoxia and SuHx at five weeks. Compared to
normoxic rats (0.17 0.03), RV mass index was increased in
the SuHx rats at five weeks (0.28 0.04, p¼ 0.002) and eight
weeks (0.27 0.04, p¼ 0.002). RV demonstrated progressive
dilatation (increasing RVEDV index) at eight weeks of
SuHx compared to normoxic rats (0.75 0.13 vs
0.56 0.1, p¼ 0.022). In RVEF, there were no significant
differences between normoxic rats and five and eight week
SuHx rats; however, demonstrating trends toward impair-
ment (RVEF¼ 68.3 5.1%, 69.4 6.9%, and 62.6 6.1%,
respectively). Stroke volume index was preserved in the
SuHx model at five and eight weeks compared to normoxia
(0.44 0.1 vs 0.5 0.04 vs 0.49 0.1). VMI after five weeks
(0.34 0.06, p¼ 0.003) and eight weeks of SuHx
(0.34 0.06, p¼ 0.002) were significantly higher than nor-
moxic rats (0.21 0.04) (Fig. 4).
Left ventricle
No differences were observed between the normoxic
and SuHx groups (normoxia, five and eight weeks, respect-
ively) in terms of LVEDV index (0.73 0.08 vs 0.74 0.06
vs 0.75 0.16), LVESV index (0.29 0.05 vs 0.24 0.04 vs
0.25 0.03), LV mass index (0.79 0.07 vs 0.82 0.09 vs
0.8 0.15), or LVEF (60.3 7.03 vs 67.83.16 vs
66.5 3.12) (Fig. 5).
LV eccentricity index
LVEI measured at systole was significantly higher in
SuHx rats at five weeks (1.2 0.07, p¼ 0.006) and in
SuHx rats at eight weeks (1.22 0.14, p¼ 0.004) compared
to normoxic rats (0.98 0.08). There were no differences
between LVEI at diastole between normoxia and SuHx at
five or eight weeks (1.06 0.05 vs 1.14 0.04 vs 1.1 0.06)
(Fig. 5).
Supplementary file demonstrates CMR variables between
normoxia and Sugen hypoxia at five and eight weeks.
Autopsy vs CMR in the measurement of RV hypertrophy
CMR images taken from a normoxic and SuHx animals
and light microscopy images of the same animals at
autopsy were compared. Although both techniques could
visually demonstrate ventricular size and wall thickness
(hypertrophy), CMR demonstrated functional aspects of
RV contraction including septal flattening and paradoxical
septal motion during systole in SuHx animals. Fig. 6 dem-
onstrates short axis CMR images ((a) to (c)) and light
microscopy images ((d) and (e)) of short axis sections of
the same rat hearts at autopsy. (b) and (c) demonstrates a
SuHx animal at the same short axis at diastole (b) and
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Fig. 2. Right ventricular systolic pressure measured by right heart catheterization (a), RV/(LVþ septum) by gross weight (b), the percentage of
remodeled vessels in a lung section (c), and immunohistochemical analysis of a-smooth muscle actin (a-SMA) staining in the smooth muscle layer
of small pulmonary arteries of the lungs ((d) to (g)). For right heart pressure analysis, the catheter was inserted into the jugular vein and guided
into the right ventricle to measure right ventricular systolic pressure (RVSP). Animals were culled, the heart was isolated, atria were removed and
RV/(LVþ septum) were measured to assess RV hypertrophy. Although there are significant differences between the normoxic group (n¼ 8) and
Sugen–hypoxic groups at five (n¼ 4) and eight weeks (n¼ 4), there were no significant differences in RVSP nor RV/(LVþ septum) at autopsy
between Sugen–hypoxia five and eight weeks. Vascular thickening was determined by smooth muscle actin antibody (ab5694, Abcam, Cambridge,
UK) staining, thickening was characterized by an increase in the vessel wall diameter of more than 50% of the arterial wall or complete occlusion.
The number of remodeled vessels over the total number of vessels present in a lung section was determined. Results are shown as mean SEM.
ANOVA test was used to compare the three groups, and if there was statistical significance, a Tukey HSD test was used for post hoc analysis.
* represents p< 0.05 and ** represents p< 0.01. For immunohistochemical analysis of a-smooth muscle actin (a-SMA) staining in the smooth
muscle layer of small pulmonary arteries of the lung, sections were viewed at 200. (d) and (f) demonstrate normoxic animals at five and eight
weeks while (e) and (g) demonstrate vascular thickening and remodeling of the pulmonary vasculature (black arrows) in Sugen–hypoxic rats at five
and eight weeks, respectively.
RVSP: RV systolic pressure; SuHx: Sugen–hypoxia; RV: right ventricle; LV: left ventricle.
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Fig. 3. Cardiac MRI short axis image taken from a long axis (a) and a short axis cine stack ((b) to (f)) of a normoxic Sprague Dawley rat. CMR
imaging was performed in a Bruker 7T (Bruker, Biospin, Germany) system. Anesthesia was induced by placing the rat in an anesthesia induction
chamber with gas flow at 2–3 l/min, and the isoflurane was delivered via a vaporizer (Vetamac, Rossville, IN) at 3–4%. After induction, animals
were then maintained at 2% (v/v) isoflurane supplemented with a constant flow of 5% (v/v) oxygen. An external water jacket was used to maintain
a core temperature of 37C. During all procedures, body temperature, ECG, and respiration were monitored using a rodent monitoring system
(Echo: Indus Instruments, Houston, TX; MRI: SA Instruments, Stony Brook, NY; Cath: Powerlab, Ad instruments, Colorado Springs, CO). Long
axis and short axis scout images were acquired so that a true short axis images could be planned using a segmented, cardiac-triggered FLASH
sequence. The short axis images were acquired with a slice thickness of 1.5 mm ensuring the entire biventricular length is covered.
LV: left ventricle; RV: right ventricle.
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systole (c). The SuHx animal demonstrated a significantly
dilated and hypertrophied RV with paradoxical septal
motion at systole. There was very good correlation between
VMI measured by CMR vs autopsy (Spearmen r¼ 0.8328,
95% CI: 0.5633–0.9422, p< 0.0001). However, MR images
demonstrate functional aspects of RV contraction including
septal flattening and paradoxical septal motion during sys-
tole due to RV pressure overload.
Fig. 4. RV end-systolic volume index (RVESVI) (a), RV end-diastolic volume index (RVEDVI) (b), RV mass index (c), RV ejection fraction (RVEF)
(d), ventricular mass index (VMI) (e), and Stroke volume index (SVI) (f) in normoxia (n¼ 8), five week Sugen–hypoxia (n¼ 4) and eight week
Sugen–hypoxia (n¼ 4). RV end-diastolic and end-systolic volumes and RV mass were determined by manual planimetry and indexed to body
surface area. RVEF was determined by ((RVEDV – RVESV)/RVEDV) 100%. A demonstrates progressive increase in RV end-systolic volume index
during the course of Sugen–hypoxia, while B demonstrates RV dilatation at eight weeks. RV mass index (c) was significantly increased in five week
and eight week Sugen–hypoxia compared to normoxic rats. RVEF (d) was preserved, however, trending toward deterioration at eight weeks.
Ventricular mass index (VMI) was calculated as the ratio between RV mass to LV mass. Interventricular septum was considered as part of the LV.
VMI maybe an alternative to RV/(LVþ septum) measured at autopsy as discussed. Results demonstrated increased VMI at five weeks and eight
weeks of Sugen–hypoxia compared to normoxic rats (e). There were no significant differences in stroke volume index (SVI) between normoxia,
five week Sugen–hypoxia and eight week Sugen–hypoxia (f). Results are shown as mean SEM. The groups were compared by ANOVA and if
there was statistical significance, a Tukey HSD test was used for post hoc.
LV: left ventricle; RV: right ventricle; SuHx: Sugen–hypoxia.
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Discussion
To the best of our knowledge, this is the first study demon-
strating longitudinal biventricular mass, volume, and
function in a PH animal model using CMR. Previous studies
had used echocardiography to examine biventricular func-
tion and structure in small animal models of PAH.7
Previous CMR studies used phase contrast imaging but
Fig. 5. LV end-systolic volume index (LVESVI) (a), LV end-diastolic volume index (LVEDVI) (b), LV mass index (c), LV ejection fraction (LVEF) (d),
LV eccentricity index (LVEI) in systole (e) and LV eccentricity index in diastole (f) are shown in normoxia (n¼ 8), Sugen–hypoxia at five weeks
(n¼ 4) and Sugen–hypoxia at eight weeks (n¼ 4). LV end-diastolic and end-systolic volumes and LV mass were determined by manual planimetry
and indexed to body surface area. LVEF was determined by ((LVEDV – LVESV)/LVEDV) 100%. There were no significant differences between the
normoxic group and different stages of Sugen–hypoxia in LVESVI, LVEDVI, LV mass index, and LVEF. Left ventricular eccentricity index (LVEI) was
defined as the ratio of the anterior-inferior and septal–posterolateral cavity dimensions at the mid-ventricular level and was measured at both
systole (e) and diastole (f). Although there were no significant differences between the three groups in the LVEI in diastole, LVEI was higher in
both Sugen–hypoxic groups compared to normoxia in systole. Previous human studies had demonstrated LVEI in systole to correlate with
pulmonary hypertension. The groups were compared by ANOVA, and if there was statistical significance, a Tukey HSD test was used for post hoc
analysis. Results are shown as mean SEM.
**: p< 0.05.
LV: left ventricle; SuHx: Sugen–hypoxia.
8 | Cardiac changes in a PH rodent model Jayasekera et al.
did not explore LV and RV volume and functional variables
known to be prognostic in PH, nor look at longitudinal
changes.10
Our study demonstrated the feasibility of CMR in a small
animal model of PAH with good spatial and temporal reso-
lution and excellent inter-observer reproducibility. The
future advantage of CMR over cardiac catheterization and
autopsy is the ability to perform imaging serially on the
same animal to look at disease progression and response
to treatment without killing the animal.
The main cause of morbidity and mortality in patients
with PAH is RV failure. It had been assumed that the cause
of RV dysfunction was alterations to the pulmonary vascu-
lature and therefore treatment focus had been centered on
improving pulmonary hemodynamics, with the assumption
that improvement in RV would follow. However, it is now
evident that cardiac response to a given level of pulmonary
hemodynamic overload is variable but important in the sub-
sequent prognosis of these patients.3 Although traditionally
right heart catheterization and post mortem studies have
been used, there is a need for non-invasive tests of RV func-
tion in animal models of PAH. In addition, we need to have
a better understanding of the longitudinal changes in ven-
tricular function in animal models of PAH. Although the
RV is the obvious focus of attention, LV dysfunction can
occur through cardiac interaction, thus simultaneous evalu-
ation of the LV is important. Echocardiography is widely
available and can be used to estimate RVSP; however, ima-
ging of the RV with its complex geometry is difficult.
The SuHx small animal model—PH
Plexiform lesions in the pulmonary vasculature are known
to be the hallmark of PAH and attempts have been made to
establish an animal model that closely mimics human dis-
ease. The SuHx model has been shown to cause severe PH
with the development of plexiform lesions. We used a SuHx
model consisting of an injection of Sugen, two weeks of
hypobaric hypoxia and three weeks or normoxia. Dean
et al. explored the effects of Metformin on the development
Fig. 6. Cardiac MR images ((a) to (c)) and light microscopy images ((d) and (e)) of short axis sections of rat hearts. (a) and (d) demonstrate a
normoxic rat. (b), (c), and (e) demonstrate a Sugen–hypoxic rat. (b) and (c) demonstrates the same animal short axis at diastole (b) and systole
(c). (f) demonstrates the correlation between RV hypertrophy assessed by weighing RV and LVþ S at autopsy and by ventricular mass index by
CMR in normoxic rats and Sugen–hypoxic rats. There was very good correlation between VMI measured by CMR vs autopsy (Spearmen
r¼ 0.8328). However, CMR images demonstrate functional aspects of RV contraction including septal flattening and paradoxical septal motion
during systole (c) due to RV pressure overload.
LV: left ventricle; RV: right ventricle; CMR: cardiac magnetic resonance; VMI: ventricular mass index.
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of PH via aromatase inhibition, a similar SuHx model was
used (Sugen þ two weeks of hypobaric hypoxia and three
weeks of normoxia).14 The study demonstrated similar
hemodynamics and RV hypertrophy compared to our
study population after eight weeks. Abe et al. investigated
the longitudinal hemodynamic and histological changes in
the model. At 13–14 weeks after Sugen, the rats had very
high RVSP (96 11 vs 21) and severe RV hypertrophy (0.76
at five weeks, 0.74 at eight weeks, and 0.74 at 13–14 weeks).6
The varying degrees of RVSP and RV hypertrophy in these
studies is likely related to the duration of exposure to hyp-
oxia, however, could also be related to the animal strain,
gender, and age at exposure.
The SuHx small animal model—RV function
In humans with PAH, progressive narrowing of the pulmon-
ary vasculature causes increased load to the RV. The RV
adaptation results in increasing wall thickness (hypertrophy)
and contractility (coupling). Ventriculo–arterial coupling pre-
serves stroke volume and ventricular efficiency. The RV then
dilates, increasing wall stress and oxygen consumption per
gram resulting in uncoupling and reduced stroke volume.15
In our study, RV hypertrophy was followed by subsequent
dilatation. However, stroke volume and RVEF were rela-
tively preserved. This was despite the presence of persistently
elevated RVSP. We believe this study represents the natural
history of RV hypertrophy and failure, demonstrating com-
pensated RV hypertrophy (adaptive remodeling) before pro-
gression into maladaptive remodeling with further RV
dilatation and RV failure, with reduction of RV output.
Adaptive vs maladaptive remodeling
Wang et al.16 hypothesized that a SuHx mouse model may
capture the transition from adaptive to maladaptive RV
remodeling including impairment in RV function by study-
ing PV measurements in vivo. The results suggested that RV
remodeling may begin to shift from adaptive to maladaptive
with increasing duration of SuHx exposure. However, for
the duration of SuHx exposure used in their study, no drop
in cardiac output was observed.16 We believe that our study
demonstrates a period of adaptive remodeling of the RV
with compensated hypertrophy with minimal RV dilatation
at later stages of the study. By lengthening the exposure to
SuHx, we may be able to identify the transition from adap-
tive to maladaptive remodeling and identify decompensated
right heart failure in this model. Most patients present to
clinical assessment when there are signs of more severe RV
dysfunction and in contrast pre-clinical SuHx model dem-
onstrate adaptive remodeling at least early in its disease
progression. This is of importance in the design of pre-
clinical studies as intervention with experimental therapeu-
tics is likely to occur at this early adaptive stage of disease
progression where RV function/stroke volume seem to be
preserved despite the presence of PAH.
Small animal model—LV function
In PAH, impaired LV performance is explained by
low RV cardiac output and direct ventricular interaction
due to inter-ventricular dyssynchrony and paradoxical
septal motion.17,18 Previous human studies have demon-
strated that patients with progressive illness demonstrated
lower LV systolic function compared to stable patients.
Previous echocardiography studies have also demonstrated
impaired LV strain and torsion in PAH patients.17
We observed preserved LV systolic function with preserved
LV mass and volume variables in this small animal model
of PAH. Although PAH animals demonstrated
paradoxical septal motion of the septum in our study, pre-
served RV output probably explains the preserved LV
function.
Conclusion
CMR is feasible in a small animal model of PAH and could
be used in pre-clinical animal studies to explore bi-ventricu-
lar structural and functional changes during the course of
illness. It is likely that the SuHx model demonstrates adap-
tive remodeling to persistently elevated pulmonary pressures
which is demonstrable by preserved RV function and stroke
volume with hypertrophy of the RV. Further longitudinal
studies are required to assess this model in detail, especially
focusing on longitudinal RV response. The search for better
animal models of PH continues because our understanding
of the pathobiology of disease and the development of new
therapeutic strategies depends on robust animal models, but
at present, no single model has all the features of human
disease.
Limitations
The study assessed rats at five and eight weeks from Sugen
exposure, while assessment later may have demonstrated
worsened hemodynamics and RV variables mimicking dis-
ease presentation in humans. The rats were anesthetized
with isoflurane, previous studies using halogenated anes-
thetics have been shown to impair RV–PA coupling; how-
ever, these effects were seen both in hypoxia and
hyperoxia.19 Future studies with late gadolinium enhance-
ment data will provide further insights into myocardial
remodeling in PAH.
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